HMR 3562

Drug Profile

HMR 3562

Latest Information Update: 31 Jan 2017

Price : $50

At a glance

  • Originator Aventis
  • Class Antibacterials; Ketolides
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 31 Jan 2017 Discontinued - Preclinical for Bacterial infections in France (unspecified route)
  • 10 Oct 2002 Suspended - Preclinical for Bacterial infections in France (unspecified route)
  • 15 Feb 2002 An in vitro study has been added to the Bacterial infections antimicrobial section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top